| 臺大學術典藏 |
2022-09-15T01:09:00Z |
Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three phase 1–2 trials
|
Drilon A.; Siena S.; Dziadziuszko R.; Barlesi F.; Krebs M.G.; Shaw A.T.; de Braud F.; Rolfo C.; Ahn M.-J.; Wolf J.; Seto T.; Cho B.C.; Patel M.R.; Chiu C.-H.; John T.; Goto K.; Karapetis C.S.; Arkenau H.-T.; Kim S.-W.; Ohe Y.; Li Y.-C.; Chae Y.K.; Chung C.H.; Otterson G.A.; Murakami H.; Chia-Chi Lin; Tan D.S.W.; Prenen H.; Riehl T.; Chow-Maneval E.; Simmons B.; Cui N.; Johnson A.; Eng S.; Wilson T.R.; Doebele R.C. |
| 臺大學術典藏 |
2022-06-27T07:00:11Z |
First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study
|
Soria J.-C.; Tan D.S.W.; Chiari R.; Wu Y.-L.; Paz-Ares L.; Wolf J.; Geater S.L.; Orlov S.; Cortinovis D.; CHONG-JEN YU; Hochmair M.; Cortot A.B.; Tsai C.-M.; Moro-Sibilot D.; Campelo R.G.; McCulloch T.; Sen P.; Dugan M.; Pantano S.; Branle F.; Massacesi C.; de Castro G.; Jr |
| 臺大學術典藏 |
2021-04-23T05:56:29Z |
Safety and efficacy of nazartinib (EGF816) in adults with EGFR-mutant non-small-cell lung carcinoma: a multicentre, open-label, phase 1 study
|
Tan D.S.-W.;Leighl N.B.;Riely G.J.;Chih-Hsin Yang;Sequist L.V.;Wolf J.;Seto T.;Felip E.;Aix S.P.;Jonnaert M.;Pan C.;Tan E.Y.;Ko J.;Moody S.E.;Kim D.-W.; Tan D.S.-W.; Leighl N.B.; Riely G.J.; CHIH-HSIN YANG; Sequist L.V.; Wolf J.; Seto T.; Felip E.; Aix S.P.; Jonnaert M.; Pan C.; Tan E.Y.; Ko J.; Moody S.E.; Kim D.-W. |
| 臺大學術典藏 |
2020-08-12T06:34:32Z |
First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study
|
Geater S.L.; Wolf J.; Paz-Ares L.; Soria J.-C.; Tan D.S.W.; Chiari R.; Wu Y.-L.; Soria J.-C.;Tan D.S.W.;Chiari R.;Wu Y.-L.;Paz-Ares L.;Wolf J.;Geater S.L.;Orlov S.;Cortinovis D.;Chong-Jen Yu;Hochmair M.;Cortot A.B.;Tsai C.-M.;Moro-Sibilot D.;Campelo R.G.;Mcculloch T.;Sen P.;Dugan M.;Pantano S.;Branle F.;Massacesi C.;De Castro G.;Jr; Orlov S.; Cortinovis D.; CHONG-JEN YU; Hochmair M.; Cortot A.B.; Tsai C.-M.; Moro-Sibilot D.; Campelo R.G.; McCulloch T.; Sen P.; Dugan M.; Pantano S.; Branle F.; Massacesi C.; de Castro G.; Jr |
| 臺大學術典藏 |
2020-08-12T06:34:32Z |
First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study
|
Geater S.L.; Wolf J.; Paz-Ares L.; Soria J.-C.; Tan D.S.W.; Chiari R.; Wu Y.-L.; Soria J.-C.;Tan D.S.W.;Chiari R.;Wu Y.-L.;Paz-Ares L.;Wolf J.;Geater S.L.;Orlov S.;Cortinovis D.;Chong-Jen Yu;Hochmair M.;Cortot A.B.;Tsai C.-M.;Moro-Sibilot D.;Campelo R.G.;Mcculloch T.;Sen P.;Dugan M.;Pantano S.;Branle F.;Massacesi C.;De Castro G.;Jr; Orlov S.; Cortinovis D.; CHONG-JEN YU; Hochmair M.; Cortot A.B.; Tsai C.-M.; Moro-Sibilot D.; Campelo R.G.; McCulloch T.; Sen P.; Dugan M.; Pantano S.; Branle F.; Massacesi C.; de Castro G.; Jr |
| 臺大學術典藏 |
2020-05-26T09:27:14Z |
Vandetanib plus pemetrexed for the second-line treatment of advanced non - small-cell lung cancer: A randomized, double-blind phase III trial
|
De Boer R.H;Arrieta ?;Chih-Hsin Yang;Gottfried M;Chan V;Raats J;De Marinis F;Abratt R.P;Wolf J;Blackhall F.H;Langmuir P;Milenkova T;Read J;Vansteenkiste J.F.; De Boer R.H; Arrieta ?; CHIH-HSIN YANG; Gottfried M; Chan V; Raats J; De Marinis F; Abratt R.P; Wolf J; Blackhall F.H; Langmuir P; Milenkova T; Read J; Vansteenkiste J.F. |
| 臺大學術典藏 |
2020-05-26T09:27:14Z |
Vandetanib plus pemetrexed for the second-line treatment of advanced non - small-cell lung cancer: A randomized, double-blind phase III trial
|
De Boer R.H;Arrieta ?;Chih-Hsin Yang;Gottfried M;Chan V;Raats J;De Marinis F;Abratt R.P;Wolf J;Blackhall F.H;Langmuir P;Milenkova T;Read J;Vansteenkiste J.F.; De Boer R.H; Arrieta ?; CHIH-HSIN YANG; Gottfried M; Chan V; Raats J; De Marinis F; Abratt R.P; Wolf J; Blackhall F.H; Langmuir P; Milenkova T; Read J; Vansteenkiste J.F. |
| 臺大學術典藏 |
2020-05-26T09:27:03Z |
Diarrhea associated with afatinib: An oral ErbB family blocker
|
Chih-Hsin Yang;Reguart N;Barinoff J;K?Hler J;Uttenreuther-Fischer M;Stammberger U;O'Brien D;Wolf J;Cohen E.E.; CHIH-HSIN YANG; Reguart N; Barinoff J; Köhler J; Uttenreuther-Fischer M; Stammberger U; O'Brien D; Wolf J; Cohen E.E. |
| 臺大學術典藏 |
2020-05-26T09:27:03Z |
Diarrhea associated with afatinib: An oral ErbB family blocker
|
Chih-Hsin Yang;Reguart N;Barinoff J;K?Hler J;Uttenreuther-Fischer M;Stammberger U;O'Brien D;Wolf J;Cohen E.E.; CHIH-HSIN YANG; Reguart N; Barinoff J; Köhler J; Uttenreuther-Fischer M; Stammberger U; O'Brien D; Wolf J; Cohen E.E. |
| 臺大學術典藏 |
2020-05-26T09:26:38Z |
Targeting RET in patients with RET-rearranged lung cancers: Results from the global, multicenter RET registry
|
Mok T.S.K; CHIH-HSIN YANG; Ou S.-H.I; Pall G; Froesch P; Zalcman G; Gandara D.R; Riess J.W; Velcheti V; Zeidler K; Diebold J; Früh M; Michels S; Monnet I; Popat S; Rosell R; Karachaliou N; Rothschild S.I; Shih J.-Y; Warth A; Muley T; Cabillic F; Mazières J; Drilon A.; Gautschi O;Milia J;Filleron T;Wolf J;Carbone D.P;Owen D;Camidge R;Narayanan V;Doebele R.C;Besse B;Remon-Masip J;Janne P.A;Awad M.M;Peled N;Byoung C.-C;Karp D.D;Van Den Heuvel M;Wakelee H.A;Neal J.W;Mok T.S.K;Chih-Hsin Yang;Ou S.-H.I;Pall G;Froesch P;Zalcman G;Gandara D.R;Riess J.W;Velcheti V;Zeidler K;Diebold J;Fr?h M;Michels S;Monnet I;Popat S;Rosell R;Karachaliou N;Rothschild S.I;Shih J.-Y;Warth A;Muley T;Cabillic F;Mazi?res J;Drilon A.; Gautschi O; Milia J; Filleron T; Wolf J; Carbone D.P; Owen D; Camidge R; Narayanan V; Doebele R.C; Besse B; Remon-Masip J; Janne P.A; Awad M.M; Peled N; Byoung C.-C; Karp D.D; Van Den Heuvel M; Wakelee H.A; Neal J.W |
